MedTrace Logo

Characterization of the Immunometabolic Signature in Long COVID-19.

NCT05758480 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2026-03-09

No results posted yet for this study

Summary

The primary objective of this study is to identify immunometabolic signatures associated with Long COVID in plasma and peripheral blood mononuclear cells (PBMC).

Conditions

Interventions

BIOLOGICAL

Blood sample (at inclusion and 6 months later)

(56ml of blood, 8 tubes) 3 heparin, 1 EDTA , 2 SST, 2 CPT

OTHER

Patient questionnaires (at inclusion and 6 months later)

(4 questionnaires) Symptoms in the last week, Fatigue Impact Scale (FIS), Short-Form 36 (SF-36) and Nijmegen.

Sponsors & Collaborators

  • University Hospital, Angers

    lead OTHER_GOV

Principal Investigators

  • Vincent DUBEE, MD, PhD · Angers University Hospital

  • Valérie DUBUS, MD · Angers University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-24
Primary Completion
2025-05-07
Completion
2025-11-03

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05758480 on ClinicalTrials.gov